Skip to main content
CHA Vaccine Research Institute logo

CHA Vaccine Research Institute — Investor Relations & Filings

Ticker · 261780 ISIN · KR7261780001 KO Manufacturing
Open in API
Filings indexed 139 across all filing types
Latest filing 2026-03-25 Major Shareholding Noti…
Country KR South Korea
Listing KO 261780

About CHA Vaccine Research Institute

http://en.chavaccine.com/

CHA Vaccine Research Institute is a research-oriented biotechnology company focused on developing vaccines and immunotherapeutics for the prevention and treatment of infectious diseases. The company's core strategy involves leveraging proprietary adjuvant platforms, such as L-pampo and L-pampo, which are based on Toll-like receptor (TLR) ligands, to enhance vaccine efficacy. Its development pipeline includes a third-generation prophylactic vaccine and a therapeutic vaccine for Hepatitis B (HBV), a recombinant vaccine for herpes zoster (shingles), and an improved influenza vaccine. In addition to its vaccine portfolio, the institute is developing immunotherapeutic proteins like recombinant Mannose-Binding Lectin (MBL) for broad-spectrum pathogen suppression.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a 주식등의 대량보유상황보고서 (Report on Large Shareholdings) filed under the Capital Markets and Financial Investment Services Act, detailing the acquisition of 3,948,813 shares (14.69%) by Solux Co., Ltd. It provides issuer, reporting person, shareholding amounts, dates, contractual details, and rationale for management influence. This corresponds exactly to a Major Shareholding Notification.
2026-03-25 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is titled “주식등의 대량보유상황보고서(약식)” and provides detailed disclosure of a party’s shareholding level, ownership percentages, transaction dates, and reasons for reporting. This corresponds to a statutory major shareholding notification when significant share ownership thresholds are crossed. It is not an earnings release, management change, or other category. Therefore, it best fits the “Major Shareholding Notification” category (Code: MRQ).
2026-03-24 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 1% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (임시주주총회). It does not contain the full proxy materials or the meeting results, but rather serves as a formal notice of the record date for shareholder rights. Given the nature of the announcement as a regulatory disclosure of corporate action, it fits best under the RNS (Regulatory Filings) category as it is a standard corporate notification.
2026-03-19 Korean
주주총회소집결의 (임시주주총회)
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) for '차백신연구소' (CHA Vaccine Institute). It details the date, time, location, and agenda items (election of directors and auditors). This type of document, which solicits shareholder participation and provides information for an upcoming meeting, is classified as a Proxy Solicitation & Information Statement.
2026-03-19 Korean
최대주주변경을수반하는주식양수도계약체결
Major Shareholding Notification Classification · 1% confidence The document is a formal regulatory filing regarding a 'Change in Largest Shareholder' (최대주주 변경) resulting from a stock purchase agreement (주식양수도 계약). This type of filing is a standard corporate disclosure in South Korea (DART system) concerning changes in control and major shareholding structure. Since it details the transfer of shares and the resulting change in the controlling entity, it falls under the category of M&A activity or significant corporate restructuring announcements. Given the specific options, 'TAR' (M&A Activity) is the most appropriate classification for a change in control/ownership transaction.
2026-03-19 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) regarding a decision for a third-party paid-in capital increase (유상증자결정) by Cha Vaccine Institute. This is a formal regulatory filing detailing the issuance of new shares, the purpose of the capital raise, the target entity (Dream High Holdings), and the pricing methodology. In the context of Korean financial filings, this type of disclosure regarding capital structure changes and share issuance falls under the 'Share Issue/Capital Change' category.
2026-03-19 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.